INDICATIONS

ABRAXANE is indicated for:

  • The treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated
  • The first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy
  • The first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine

INDICATIONS

ABRAXANE is indicated for:

  • The treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated
  • The first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy
  • The first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine